New guidance outlines use of first immunotherapy for children newly diagnosed with type 1 diabetes

AI Summary

New guidance describes the use of an approved immunotherapy for children ages 8 to 17 newly diagnosed with type 1 diabetes. The treatment targets the autoimmune disease underlying diabetes, rather than only managing blood sugar with insulin.

For the first time, children ages 8 to 17 who are newly diagnosed with type 1 diabetes have access to an approved treatment that targets the underlying autoimmune disease, rather than solely managing blood sugar levels with insulin.